炎症反应与凋亡的调控:sgp130Fc作为脓毒症相关肾损伤的潜在治疗药物
本研究纳入60例患者,分为脓毒症组(n=20)、脓毒症相关肾损伤(SAKI)I-II期组(n=20)和SAKI III期组(n=20),观察到急性肾损伤严重程度与IL-6水平呈正相关。在雄性C57BL/6J小鼠中通过盲肠结扎穿孔诱导脓毒症,研究sgp130Fc(IL-6反式信号选择性抑制剂)的治疗作用,并对肾组织行RNA-seq转录组分析。GO富集分析确认炎症相关通路显著富集,并经超几何检验验证。sgp130Fc通过抑制IL-6/sIL-6R信号、调控STAT3/NF-κB通路减轻SAKI,表现为促炎介质释放减少、Bax下调、Bcl-2上调及肾损伤标志物KIM-1和NGAL降低。作者认为sgp130Fc具有肾脏保护作用,支持进一步临床研究。
要点
- 在60例患者中观察到急性肾损伤严重程度与IL-6水平呈正相关(脓毒症组n=20,SAKI I-II期组n=20,SAKI III期组n=20)。
- 脓毒症小鼠肾组织RNA-seq的GO富集分析确认炎症相关通路显著富集,并经炎症特异性基因集超几何检验验证。
- sgp130Fc通过抑制IL-6/sIL-6R信号及调控STAT3/NF-κB通路减轻SAKI。
- sgp130Fc使促炎介质释放减少、Bax下调、Bcl-2上调,并降低肾损伤标志物KIM-1和NGAL。
- 作者认为sgp130Fc在SAKI中具有治疗潜力,并支持进一步临床研究。
适用人群与场景
- 脓毒症患者(Sepsis组n=20)、脓毒症相关肾损伤I-II期患者(n=20)及III期患者(n=20)用于IL-6水平与肾损伤严重程度的相关性分析。
- 雄性C57BL/6J小鼠通过盲肠结扎穿孔诱导脓毒症,用于sgp130Fc治疗研究。
研究设计与关键结果
- 研究类型为临床队列(60例患者)联合小鼠脓毒症模型实验;患者分为脓毒症组(n=20)、SAKI I-II期组(n=20)、SAKI III期组(n=20),观察到急性肾损伤严重程度与IL-6水平呈正相关。
- 小鼠经盲肠结扎穿孔诱导脓毒症后,肾组织RNA-seq转录组分析识别差异表达基因,GO富集分析确认炎症相关通路显著富集,并经炎症特异性基因集超几何检验验证。
- sgp130Fc干预通过抑制IL-6/sIL-6R信号及调控STAT3/NF-κB通路减轻SAKI,表现为促炎介质释放减少。
- sgp130Fc干预使凋亡减少,表现为Bax下调、Bcl-2上调,并降低肾损伤标志物KIM-1和NGAL。
证据类型、等级与局限
- 证据类型:患者队列(n=60)联合小鼠脓毒症模型实验(盲肠结扎穿孔诱导),包含RNA-seq转录组分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为sgp130Fc在SAKI中具有治疗潜力,并支持进一步临床研究。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVE: This study aims to evaluate the therapeutic potential and underlying mechanisms of sgp130Fc, a selective inhibitor of interleukin-6 (IL-6) trans-signaling, in mitigating sepsis-associated kidney injury (SAKI).
METHODS: A cohort of 60 patients was stratified into three groups: Sepsis group (n = 20), SAKI Stages I-II group (n = 20), and SAKI Stage III group (n = 20). A positive correlation was observed between acute kidney injury severity and IL-6 levels. In vivo , sepsis was induced in male C57BL/6J mice via cecal ligation and puncture. The therapeutic effects of sgp130Fc, a selective inhibitor of IL-6 trans-signaling, were investigated. Transcriptomic analysis (RNA-seq) of renal tissue from septic mice identified differentially expressed genes. Gene ontology (GO) enrichment analysis confirmed significant enrichment of inflammation-related pathways, further validated using hypergeometric testing with an inflammation-specific gene set. Expression of downstream signaling molecules [signal transducer and activator of transcription 3 (STAT3), nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB)], apoptosis-related proteins [B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax)], and renal injury biomarkers [kidney injury molecule-1 (KIM-1), neutrophil gelatinase-associated lipocalin (NGAL)] was also assessed.
RESULTS: Administration of sgp130Fc attenuated SAKI through inhibition of IL-6/sIL-6R signaling and modulation of the STAT3/NF-κB pathway. This intervention resulted in reduced release of pro-inflammatory mediators and decreased apoptosis as evidenced by downregulation of Bax, upregulation of Bcl-2, and reductions in renal injury markers KIM-1 and NGAL.
CONCLUSION: sgp130Fc confers renoprotective effects in a murine model of sepsis by selectively targeting the IL-6 trans-signaling pathway and modulating STAT3/NF-κB signaling to inhibit inflammation and apoptosis. These findings highlight the therapeutic potential of sgp130Fc in SAKI and support further clinical investigation.
参考来源
- Liu X, Liu Y, Chen Y, et al. Regulation of Inflammatory Responses and Apoptosis: sgp130Fc as a Potential Therapeutic Agent for Sepsis-Associated Kidney Injury. Shock. 2026. PMID: 41886623. doi:10.1097/SHK.0000000000002843
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。